Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed glioblastoma
• Measurable disease by MRI
• Completed standard first-line treatment for glioblastoma including surgery (unless not received due to anatomical location), radiotherapy and temozolomide (last dose given at least 28 days prior to enrollment)
• * No other prior treatment for glioblastoma except Gliadel or steroids
• Recurrent or progressive disease after standard first-line treatment
• * No disease progression within 3 months of completion of radiotherapy
• No intra- or peri-tumoral hemorrhage
• PATIENT CHARACTERISTICS:
• Karnofsky performance status 70-100%
• Mini-mental status score ≥ 15
• Life expectancy ≥ 12 weeks
• Serum bilirubin, ALT/AST, creatinine, and urine protein normal
• Adequate bone marrow reserve
• Not pregnant or nursing
• Normal ECG
• No history of familial long QT syndrome
• No absorption or swallowing difficulties
• No uncontrolled hypertension or cardiac ventricular arrhythmias
• No current or history of uncontrolled hypertension or requiring maximal doses of calcium channel blockers
• No severe or uncontrolled disease
• No history of lung disease
• No recent hemorrhage or hemoptysis
• No known hypersensitivity to cediranib maleate, gefitinib, or any excipients
• No history of other malignancies except adequately treated basal cell or squamous cell carcinoma or carcinoma in situ within the past 5 years, unless disease-free for 2 years with tissue diagnosis
• No known HIV positivity
• No known hepatitis B or C infection
• No unhealed surgical incision
• Not involved in planning or conducting this study
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• Recovered from prior anticancer therapy, including radiotherapy
• At least 3 months since prior cranial radiation
• At least 30 days since prior investigational drugs
• At least 28 days since prior craniotomy
• At least 2 weeks since prior enzyme-inducing antiepileptic drugs
• At least 2 weeks since prior and no concurrent dexamethasone (\> 8 mg/day) or equivalent
• At least 14 days since prior major surgery or brain biopsy
• No concurrent steroids OR on stable dose 5 days prior to baseline MRI
• No other concurrent anticancer therapy, except for steroids (dexamethasone only)
• No previous enrollment on the current study
• No prior inhibitors of angiogenesis, EGFR, or downstream targets
• No prior radiosurgery or brachytherapy